Case Report: The First Case of Paradoxical Skin Lesions Induced by Xeligekimab in a Patient With SAPHO Syndrome
- 13 April 2026
- journal article
- letter
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 29 (4) , e70643
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Xeligekimab, an Interleukin-17A Antagonist for Active Radiographic Axial Spondyloarthritis in Chinese Patients: 16- and 48-Week Results from a Phase III, Randomized, Double-Blind, Placebo-Controlled StudyBioDrugs, 2025
- JAK Inhibitors for Treatment of SAPHO Syndrome: A Systematic Review of 72 CasesACR Open Rheumatology, 2025
- Paradoxical skin lesions induced by IL-17 inhibitors in SAPHO syndromeJournal of Dermatological Treatment, 2023
- Treatment and monitoring of SAPHO syndrome: a systematic reviewRMD Open, 2023
- SAPHO syndrome: current clinical, diagnostic and treatment approachesRheumatology International, 2023
- Paradoxical Reactions to Anti-TNFα and Anti-IL-17 Treatment in Psoriasis Patients: Are Skin and/or Gut Microbiota Involved?Dermatology and Therapy, 2023
- Eczematous eruption during anti‐interleukin 17 treatment of psoriasis: an emerging conditionBritish Journal of Dermatology, 2019
- Atopic-like dermatitis after secukinumab injection: A case reportDermatologic Therapy, 2018
- Analysis of anti-tumour necrosis factor-induced skin lesions reveals strong T helper 1 activation with some distinct immunological characteristicsBritish Journal of Dermatology, 2017
- Dual Inhibition of Interleukin-23 and Interleukin-17 Offers Superior Efficacy in Mouse Models of AutoimmunityThe Journal of Pharmacology and Experimental Therapeutics, 2015